A polymorphism of DRD2 gene and brain atrophy in methamphetamine psychosis

Ann N Y Acad Sci. 2004 Oct:1025:307-15. doi: 10.1196/annals.1316.038.

Abstract

Our group, Ujike et al., recently reported that the A1 allele of TaqI A polymorphism of the dopamine receptor D2 (DRD2) gene, associated with transient psychosis, significantly differs from that of patients with prolonged psychosis in methamphetamine psychosis. Therefore, we examined the association between the TaqI A polymorphism of the DRD2 gene and the brain MRI view for patients with methamphetamine psychosis. The subjects underwent brain MRI scans using the FLAIR method. Genotyping was performed by PCR-RFLP methods using genomic DNA extracted from peripheral blood by the phenol method. Ten subjects had the A1/A2 genotype, eleven subjects had the A2/A2 genotype, and no subject had the A1/A1 genotype. The domain size, including the thalamus and basal ganglia that were inside each side of the putamens, did not differ between the three groups (the A1/A2-group, the A2/A2-group, and the young healthy person group). In the comparison based on this domain, the temporal lobe tended to narrow in the A2/A2-group compared to the A1/A2-group (P = .06). The other domain (cerebrum, corpus callosum, etc.) showed no difference between the A1/A2-group and the A2/A2-group. It is suggested that in methamphetamine psychosis the TaqI A polymorphism not only regulates prolongation of psychosis symptoms but also influences the form of the temporal lobe.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Atrophy
  • Brain / metabolism*
  • Brain / pathology*
  • Genotype
  • Humans
  • Magnetic Resonance Imaging / methods
  • Male
  • Methamphetamine*
  • Middle Aged
  • Polymorphism, Genetic / genetics*
  • Psychoses, Substance-Induced / genetics*
  • Psychoses, Substance-Induced / pathology
  • Receptors, Dopamine D2 / genetics*

Substances

  • Receptors, Dopamine D2
  • Methamphetamine